I. POLICY

Reduction mammoplasty may be considered **medically necessary** for the treatment of macromastia when ALL of the following well-documented clinical symptoms are present:

- Documentation of a minimum 6-week history of shoulder, neck, or back pain related to macromastia that is not responsive to conservative therapy, such as an appropriate support bra, exercises, heat/cold treatment, and appropriate non-steroidal anti-inflammatory agents/muscle relaxants.
- Recurrent or chronic intertrigo between the pendulous breast and the chest wall.
- Photographic confirmation of macromastia, shoulder grooving and/or chronic intertrigo.
- Estimated amount of breast tissue to be removed is **ANY** of the following:
  - An estimated minimum of 500 grams of tissue per breast will be removed in women of average stature.
  - Estimated amount is **less than** 500 grams of tissue per breast AND corresponds to body surface area (BSA) on the Schnur sliding scale below for women of small stature:

<table>
<thead>
<tr>
<th>Body Surface Area BSA (m²)</th>
<th>Weight of Tissue Removed From Each Breast in Grams</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.40</td>
<td>225</td>
</tr>
<tr>
<td>1.45</td>
<td>240</td>
</tr>
<tr>
<td>1.50</td>
<td>260</td>
</tr>
<tr>
<td>1.55</td>
<td>285</td>
</tr>
<tr>
<td>1.60</td>
<td>310</td>
</tr>
<tr>
<td>1.65</td>
<td>340</td>
</tr>
<tr>
<td>1.70</td>
<td>370</td>
</tr>
<tr>
<td>1.75</td>
<td>405</td>
</tr>
<tr>
<td>1.80</td>
<td>440</td>
</tr>
<tr>
<td>1.85</td>
<td>490</td>
</tr>
</tbody>
</table>

Formula for calculation of BSA:

$$\text{BSA (in m}^2\text{) = [height (cm)]}^{0.718} \times [\text{weight (kg)}]^{0.427} \times 0.007449$$
Reduction mammoplasty in order to reduce the contralateral breast (for symmetry purposes) is considered medically necessary for congenital anomalies (eg, Poland's syndrome, breast hypoplasia or absence) when ALL the following criteria are met:

- 50% or greater deformity or a difference of 2 cup sizes in the contralateral breast; AND
- Photographic documentation of the deformity; AND
- Tanner score (pubic hair) of 5 (if age < 18 [eighteen]) years of age.

Reduction mammoplasty is considered a reconstructive procedure and medically necessary when performed on the unaffected breast following previous radical surgery for disease when the purpose is to provide symmetry with the breast on which the mastectomy has been performed. (Act 51 of 1997).

Cross-reference:

MP-1.103 Reconstructive Breast Surgery/Management of Breast Implants
MP-1.129 Surgical Treatment of Bilateral Gynecomastia
MP-1.036 Prophylactic Mastectomy and Prophylactic Bilateral Oophorectomy
MP-1.004 Cosmetic and Reconstructive Surgery

II. PRODUCT VARIATIONS

[N] Capital Cares 4 Kids
[N] PPO
[N] HMO
[N] SeniorBlue HMO
[N] SeniorBlue PPO

[Y] Indemnity
[Y] SpecialCare
[N] POS
[Y] FEP PPO*

*Refer to FEP Medical Policy Manual MP-7.01.21 Reduction Mammoplasty for Breast Related Symptoms. The FEP Medical Policy manual can be found at: [www.fepblue.org](http://www.fepblue.org)
Reduction mammoplasty is a surgical procedure designed to remove a variable proportion of breast tissue.

Macromastia, or gigantomastia, is an ill-defined term that describes breast hyperplasia or hypertrophy. Macromastia may result in clinical symptoms such as shoulder, neck, or back pain, or recurrent intertrigo in the mammary folds. In addition, macromastia may be associated with psychosocial or emotional disturbances related to the large breast size. Reduction mammoplasty is a surgical procedure designed to remove a variable proportion of breast tissue to address emotional and psychosocial issues and/or relieve the associated clinical symptoms.

IV. RATIONALE

This policy is updated with searches of the MEDLINE database. The most recent literature search was performed for the period of September 2012 through September 2013. The following is a summary of the key findings to date.

While the literature search identified many articles that discuss the surgical technique of reduction mammoplasty and document that reduction mammoplasty is associated with a relief of physical and psychosocial symptoms, (1-9) the medical policy has always focused on the distinction of whether the proposed reduction mammoplasty is medically necessary or cosmetic in nature. For some patients the presence of medical indications is clear-cut, i.e., a clear documentation of recurrent intertrigo, or ulceration secondary to shoulder grooving. However, for the majority of patients, the documentation between a cosmetic and medically necessary procedure will be unclear and subjective in nature. Criteria for medically necessary reduction mammoplasty are not well-addressed in the published medical literature, and thus the optimal patient selection criteria cannot rely on an evidence-based approach. Therefore, the policy guidelines do not endorse a particular set of patient selection criteria, i.e., the use of photographs, amount of breast tissue removed, or a combination of approaches.

Breast Weight

The following discussion focuses the published literature addressing the use of weight of excised breast as coverage criteria. In 2001, Krieger and Lesavoy reported on a survey of managed care policies regarding reduction mammoplasty. (10) Most of the respondents to the survey stated that they use weight of excised tissue as the main criterion for allowing the procedure. The average cutoff value for this determination was 472 g. While 500 g appears to be a commonly cited cutoff weight of excised tissue, there appears to be no documentation in the literature as to the sensitivity and specificity of this value in distinguishing cosmetic from medically necessary procedures. (11) Also, the use of a single weight cutoff does not address the issue of the relationship between body surface area and weight of excised tissue. In 1991, Schnur et al., at the request of third-party payers, developed a sliding scale. (11) This sliding
scale was based on survey responses of 92 of 200 solicited plastic surgeons, who reported the height, weight, and amount of breast tissue removed from each breast from the last 15 to 20 reduction mammoplasties that had been performed. The surgeons were also asked if the procedures were performed for cosmetic or medically necessary reasons. The data were then used to create a chart relating the body surface area and the cutoff weight of breast tissue removed according to the 5th percentile and 22nd percentile lines. Based on their estimates, those with breast weight above the 22nd percentile line likely had the procedure performed for medical reasons, while those whose weight fell between the 5th percentile line likely had the procedure performed for cosmetic reasons, and those falling between the lines had the procedure formed for mixed reasons. (See Appendix for the Schnur Sliding Scale.)

In 1999, Schnur reviewed the experience of the sliding scale as a coverage criterion and reported that while many payers had adopted this scale, many had also misused it. The author pointed out that if a payer uses weight of resected tissue as a coverage criterion, then if the weight falls below the 5th percentile line, the reduction mammoplasty would be considered cosmetic, above the 22nd percentile line would be considered medically necessary, and those that fell between these lines would be considered on a case-by-case basis. The author also questions the frequent requirement that a woman be within 20% of her ideal body weight. While weight loss might indeed relieve symptoms, durable weight loss is notoriously difficult and may be unrealistic in many cases. However, in 2003, Platt et al. reported on a prospective study of 30 women which found wound breakdown was significantly greater in women with a body mass index (BMI) of 26.3 or greater (33%) compared to BMI of less than 26.3 (10%). Delayed healing was also associated with high BMI.

In 2012, Gonzalez et al. reported on 178 patients who had breast reduction surgery primarily for symptomatic macromastia. Patients completed the Breast Q questionnaire once after surgery, and retrospective chart reviews were completed to assess patient outcomes and determine whether any correlation exists between outcomes and patient size or amount of breast tissue removed. Most patients responded to the surgery with satisfaction with a mean response on the Breast Q questionnaire of 2.8 (2, somewhat agree; 3, definitely agree). The mean BMI of patients was 28.3 kg/m and correlated significantly with the amount of breast tissue removed (p<0.0001). The mean amount of breast tissue removed was 1220.9 g but did not correlate significantly with patient quality-of-life responses (p=0.57).

Functional Impairment

Singh and Losken, in 2012, reported on a systematic review of studies reporting outcomes after reduction mammoplasty. The reviewers found reduction mammoplasty improves functional outcomes including pain, breathing, sleep, and headaches. Additional psychological outcomes noted in the review include improvements in self-esteem, sexual function, and quality of life.

In 2002, Kerrigan et al. published the results of the BRAVO (Breast Reduction: Assessment of Value and Outcomes) study, a registry of 179 women undergoing reduction mammoplasty. Women were asked to complete quality-of-life questionnaires and a physical symptom count both before and after surgery. The physical symptom count focused on the number of
symptoms present that were specific to breast hypertrophy and included upper back pain, rashes, bra strap grooves, neck pain, shoulder pain, numbness, and arm pain. In addition, the weight and volume of resected tissue were recorded. Results were compared to a control group of patients with breast hypertrophy, defined as size DD bra cup, and normal-sized breasts, who were recruited from the general population. The authors propose that the presence of 2 physical symptoms might be an appropriate cutoff for determining medical necessity for breast reduction. For example, while 71.6% of the hypertrophic controls reported none or 1 symptom, only 12.4% of those considered surgical candidates reported none or one symptom. This observation is difficult to evaluate because the study does not report how surgical candidacy was determined. The authors also reported that none of the traditional criteria for determining medical necessity for breast reduction surgery (height, weight, body mass index, bra cup size, or weight of resected breast tissue) had a statistically significant relationship with outcome improvement. The authors conclude that the determination of medical necessity should be based on patients’ self-reported symptoms rather than more objectively measured criteria, such as weight of excised breast tissue.

In 2008, Sabino Neto et al. reported on a study to assess functional capacity in which 100 patients, ages 18-55 years, were randomized to receive reduction mammoplasty or be placed on a waiting list to serve as a control group. (7) Patient exclusion criteria included body mass index greater than 30 kg/m², asymmetry in mammary hypertrophy, chronic disease, smoking, or daily medication use. Forty-six patients from each group completed the study. At the onset of the study and 6 months later, patients were assessed for functional capacity using the Roland-Morris instrument (0=best performance, 24=worst performance) and for pain using a visual analog scale (VAS). The reduction mammoplasty group showed improvement in functional status with an average score of 5.9 preoperatively to 1.2 within 6 months postoperatively (p<0.001 for pre-/post comparison within the mammoplasty group) versus an unchanged average score of 6.2 in the control group on the first and second evaluations. Additionally, pain in the lower back region decreased on VAS from an average of 5.7 preoperatively to 1.3 postoperatively (p<0.001 for pre-/post comparison within the mammoplasty group) versus VAS average scores in the control group of 6.0 and 5.3 on the first and second evaluations, respectively (no significant change). Three patients did not report any improvement in low back pain after surgery. The authors noted a need for exercise programs after surgery to improve posture malpositions developed after years of mammary hypertrophy.

Also in 2008, Saariniemi et al. reported on a study to assess quality of life and pain in which 82 patients were randomized to reduction mammoplasty or a nonoperative group in which patients were evaluated at the onset of the study and 6 months later.(9) The authors reported the mammoplasty group had significant improvements in quality of life, as measured by the physical summary score of the Short-Form (SF)-36 quality-of-life questionnaire (change of +9.7 vs. +0.7, p<0.0001), the utility index score (SF-6D) (+17.5 vs. +0.6), the index score of quality of life (SF-15D) (+8.6 vs. +0.06, p<0.0001), and the SF-36 mental summary score (+7.8 vs. -1.0, p<0.002). There were also improvements in breast-related symptoms, as
measured by the Finnish Breast-Associated Symptoms questionnaire score (-47.9 vs. -3.5, p<0.0001), and the Finnish Pain Questionnaire score (-21.5 vs. -1.0, p<0.0001).

Iwuagwu et al. reported on 73 patients randomized to receive reduction mammoplasty within 6 weeks or after a 6-month waiting period to assess lung function.(8) All patients had symptoms related to macromastia. Postoperative lung function correlated with the weight of breast tissue removed, but there were no significant improvements in any lung function parameters for the mammoplasty group compared to control. This is in contrast to previous studies, such as Cunha et al. who reported improvements in lung function after reduction mammoplasty in 12 patients followed prospectively in a cohort study.(17) Arterial blood gases did not differ significantly pre- or postoperatively,

Complications

Thibaudeau et al., in 2010, conducted a systematic review to evaluate breastfeeding after reduction mammoplasty. (18) After a review of literature from 1950 through December 2008, the authors concluded reduction mammoplasty does not reduce the ability to breastfeed. In women who have had reduction mammoplasty, breastfeeding was found to be comparable for the first month postpartum in the general population in North America.

In 2011, Chen et al. reported on a review of claims data to compare complication rates after breast surgery in 2403 obese and 5597 nonobese patients. (19) Of these patients, breast reduction was performed in 1939 (80.7%) in the study group and 3569 (63.8%) in the control group. Obese patients had significantly more claims for complications within 30 days after breast reduction surgery than nonobese patients (14.6% vs. 1.7%, respectively, p<0.001). Complications included inflammation, infection, pain, and seroma/hematoma development. Also in 2011, Shermak et al. reported on a review of claims data to compare complication rates in relation to age after breast reduction surgery in 1192 patients.(20) Infection occurred more frequently in patients older than 50 years of age (odds ratio [OR]=2.7; p=0.003). Additionally, women older than 50 years also experienced more wound healing problems (OR=1.6; p=0.09) and reoperative wound debridement (OR=5.1; p=0.07).

Ongoing Clinical Trials

A previously reported ongoing trial (online site ClinicalTrials.gov NCT01297621) randomized 60 patients to evaluate patient satisfaction, sexuality, and physical activity outcomes after reduction mammoplasty was completed in June 2013. As of October 9, 2013 there were no reported results for this study, which was carried out in Brazil, and there were no additional active clinical trials that addressed functional outcomes for reduction mammoplasty.

Summary

Reduction mammoplasty is a surgical procedure designed to remove a variable proportion of breast tissue. The available evidence from randomized controlled and prospective studies indicates that reduction mammoplasty is effective at decreasing breast-related symptoms such as pain and discomfort. There is also evidence that functional limitations related to breast hypertrophy are improved following reduction mammoplasty. Therefore, the available evidence for reduction mammoplasty is sufficient to demonstrate improvements in net health
outcome. Reduction mammoplasty may be considered medically necessary in patients with macromastia, who have a minimum 6-week history of shoulder, neck, or back pain that is not responsive to conservative therapy, and not caused by any other identifiable condition. Reduction mammoplasty may also be considered medically necessary in patients with recurrent or chronic intertrigo between the pendulous breast and the chest wall.

**Practice Guidelines and Position Statements**

The American Society of Plastic Surgeons (ASPS) issued practice guidelines and a companion document on criteria for third-party payers for reduction mammoplasty.(21-23) The ASPS indicates level I evidence has shown reduction mammoplasty is effective in treating symptomatic breast hypertrophy which “is defined as a syndrome of persistent neck and shoulder pain, painful shoulder grooving from brassiere straps, chronic intertriginous rash of the inframammary fold, and frequent episodes of headache, backache, and neuropathies caused by heavy breasts caused by an increase in the volume and weight of breast tissue beyond normal proportions.” The ASPS also indicates volume or weight of breast tissue resection should not be criteria for reduction mammoplasty. If 2 or more symptoms are present all or most of the time, reduction mammoplasty is appropriate.

**V. DEFINITIONS**

**ACT 51 OF 1997 –THE MASTECTOMY ACT:** PA mandate that prohibits health insurance companies from requiring mastectomies to be performed on an outpatient basis. Other requirements include coverage for: One home health visit within 48 hours after discharge when the discharge is within 48 hours of the admission for the mastectomy; Reconstructive surgery, including surgery to re-establish symmetry and mastectomy –related prosthetic devices. **COSMETIC SURGERY:** An elective procedure performed primarily to change a person’s appearance by surgically altering a physical characteristic that does not prohibit normal function, but is considered unpleasant or unsightly. **INTERTRIGO:** A superficial dermatitis occurring on apposed skin surfaces, such as the axillae, creases of the neck, intergluteal fold, groin, between the toes and beneath pendulous breasts, with obesity being a predisposing factor, caused by moisture, friction, warmth and sweat retention and characterized by erythema, maceration, burning, itching and sometimes erosions, fissures and exudations and secondary infections. **RECONSTRUCTIVE SURGERY:** A procedure performed to improve or correct a functional impairment, restore a bodily function or correct a deformity resulting from birth defect or accidental injury. The fact that a member might suffer psychological consequences from a deformity does not, in the absence of bodily functional impairment, qualify surgery as being reconstructive surgery.
SCHNUR SLIDING SCALE is an evaluation method for physicians to use on individuals considering breast reduction surgery. This method was developed by a plastic surgeon for use in a study that was done to determine the number of women who had breast reduction surgery for medical reasons only. Body surface area, along with average weight of breast tissue removed is incorporated into the chart.

VI. BENEFIT VARIATIONS

The existence of this medical policy does not mean that this service is a covered benefit under the member’s contract. Benefit determinations should be based in all cases on the applicable contract language. Medical policies do not constitute a description of benefits. A member’s individual or group customer benefits govern which services are covered, which are excluded, and which are subject to benefit limits and which require preauthorization. Members and providers should consult the member’s benefit information or contact Capital for benefit information.

VII. DISCLAIMER

Capital’s medical policies are developed to assist in administering a member’s benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member’s benefit information, the benefit information will govern. Capital considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.

VIII. CODING INFORMATION

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Covered when medically necessary:

<table>
<thead>
<tr>
<th>CPT Codes®</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>19318</td>
<td></td>
</tr>
</tbody>
</table>

**ICD-9-CM Diagnosis Code** | **Description**
--- | ---
339.10 | TENSION TYPE HEADACHE, UNSPECIFIED
339.11 | EPISODIC TENSION TYPE HEADACHE
339.12 | CHRONIC TENSION TYPE HEADACHE
611.1 | HYPERTROPHY OF BREAST
611.71 | MASTODYNIA
695.89 | OTHER SPECIFIED ERYTHEMATOUS CONDITION
707.8 | CHRONIC ULCER OF OTHER SPECIFIED SITES
719.41 | PAIN IN JOINT, SHOULDER REGION
723.1 | CERVICALGIA
724.1 | PAIN IN THORACIC SPINE
724.5 | UNSPECIFIED BACKACHE
737.10 | KYPHOSIS (ACQUIRED) (POSTURAL)
782.0 | DISTURBANCE OF SKIN SENSATION
784.0 | HEADACHE

*If applicable, please see Medicare LCD or NCD for additional covered diagnoses.

**The following ICD-10 diagnosis codes will be effective October 1, 2015:**

| ICD-10-CM Diagnosis Code* | Description |
--- | ---
G44.201 | Tension-type headache, unspecified, intractable
G44.209 | Tension-type headache, unspecified, not intractable
G44.211 | Episodic tension-type headache, intractable
G44.219 | Episodic tension-type headache, not intractable
G44.229 | Chronic tension-type headache, not intractable
N62 | Hypertrophy of breast
N64.4 | Mastodynia
L26 | Exfoliative dermatitis
L30.4 | Erythema intertrigo
L53.8 | Other specified erythematous conditions
L54 | Erythema in diseases classified elsewhere
L92.0 | Granuloma annulare
L95.1 | Erythema elevatum diutinum
L98.2 | Febrile neutrophilic dermatosis [Sweet]
L98.499 | Non-pressure chronic ulcer of skin of other sites with unspecified severity
M25.511 | Pain in right shoulder
### IX. REFERENCES


MEDICAL POLICY

<table>
<thead>
<tr>
<th>POLICY TITLE</th>
<th>REDUCTION MAMMOPLASTY</th>
</tr>
</thead>
<tbody>
<tr>
<td>POLICY NUMBER</td>
<td>MP-1.013</td>
</tr>
</tbody>
</table>


Other sources

Centers for Medicare and Medicaid Services (CMS) National Coverage Determination (NCD) 140.2 Breast Reconstruction Following Mastectomy. Effective 1/1/97. CMS [Website]:

X. POLICY HISTORY

<table>
<thead>
<tr>
<th>MP 1.013</th>
<th>CAC 3/25/03</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CAC 11/30/05</td>
</tr>
<tr>
<td></td>
<td>CAC 11/29/05</td>
</tr>
<tr>
<td></td>
<td>CAC 11/28/06</td>
</tr>
<tr>
<td></td>
<td>CAC 4/24/07</td>
</tr>
<tr>
<td></td>
<td>CAC 5/27/08</td>
</tr>
<tr>
<td></td>
<td>CAC 11/24/09 Consensus Review</td>
</tr>
<tr>
<td></td>
<td>CAC 11/30/10 Consensus Review</td>
</tr>
<tr>
<td>CAC 7/26/11</td>
<td>Adopted BCBSA criteria regarding documentation of shoulder, neck or back pain and intertrigo. Revised policy criteria regarding photographs and estimated amount of tissue to be removed according to selected BCBSA policy guidelines. Removed all information regarding gynecomastia and created a separate policy.</td>
</tr>
<tr>
<td>CAC 8/28/12</td>
<td>Policy statement changed to indicate intertrigo must be recurrent or chronic. To remain as consensus review. References updated. Added FEP variation to reference MP-7.01.21 Reduction Mammaplasty Codes reviewed 8/21/12 klr</td>
</tr>
<tr>
<td>CAC 6/4/2013</td>
<td>Minor. Added statement indicating reduction mammaplasty in order to reduce the contralateral breast (for symmetry purposes) is considered medically necessary for congenital anomalies (eg, Poland's syndrome, breast hypoplasia or absence) when specific criteria are met.</td>
</tr>
<tr>
<td>CAC 3/25/14</td>
<td>Consensus. No change to policy statements. References reviewed. Rationale section added.</td>
</tr>
</tbody>
</table>

Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies.